tradingkey.logo

Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing

ReutersDec 23, 2025 2:01 PM

- Phio Pharmaceuticals Corp PHIO.O:

  • PHIO PHARMACEUTICALS CORP - TO BEGIN TOXICOLOGY STUDY FOR PH-762 BEFORE HUMAN TRIALS - SEC FILING

  • PHIO PHARMACEUTICALS CORP - NO DOSE-LIMITING TOXICITIES IN PH-762 TRIAL - SEC FILING

  • PHIO PHARMACEUTICALS CORP - INITIATIVES CONTINUING TO ADVANCE DELIVERY OF COMMERCIALLY VIABLE DRUG PRODUCT IN 2026

  • PHIO PHARMACEUTICALS CORP - PH-762 HAS BEEN WELL TOLERATED IN ALL ENROLLED PATIENTS IN EACH ESCALATING DOSE COHORT

Source text: [ID:n0001437749-25-038607]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI